secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0000105770-24-000009
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharma Q4 adj EPS flat YoY at $1.83; FY24 adj EPS guidance $7.50-$7.75 vs $8.08 in FY23
--------------------------------------------------------------------------------

- Q4 net sales $732.0M (+3.3% YoY); full-year net sales $2.950B (+2.2% YoY).
- Q4 reported EPS $1.83 (+34.6% YoY); full-year reported EPS $7.88 (+1.9% YoY).
- FY24 guidance: net sales $3.000B-$3.025B; adjusted EPS $7.50-$7.75; organic sales growth ~2%-3%.
- Proprietary Products organic sales down 0.3% Q4; COVID headwinds cited; excluding COVID, high-single-digit growth.
- FY23 free cash flow $414.5M (down 5.7%); repurchased 1.27M shares for $438.3M at avg $346.34.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577024000009/0000105770-24-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577024000009/wst-20240215.htm
  HTML page:      https://secwatch.observer/filing/0000105770-24-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer